Fig. 3 | Genetics in Medicine

Fig. 3

From: Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting

Fig. 3

Time to escalation and de-escalation of P2Y12 inhibitor therapy by CYP2C19 status. The cumulative frequency of initiating prasugrel or ticagrelor maintenance therapy in IM/PMs (N = 329) and UM/RM/NMs (N = 734) is presented as a function of time following the index percutaneous coronary intervention (PCI) procedure. IM intermediate metabolizer, NM normal metabolizer, PM poor metabolizer, RM rapid metabolizer, UM ultrarapid metabolizer.

Back to article page